Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers.
The ability of a cancer vaccine to elicit a specific measurable T-cell response is increasingly being used to prioritize immunization strategies for therapeutic development. Knowing the optimal time during a vaccine regimen to measure the development of tumor-specific immunity would greatly facilitate the assessment of T-cell responses. The purpose of this study was to overview the kinetics of HER-2/neu-specific T-cell immunity evolution during and after the administration of HER-2/neu peptide-based vaccination in the adjuvant setting. Furthermore, we questioned whether the presence of preexistent HER-2/neu T-cell immunity or the timing of immunity development over the course of active immunization influenced the intensity of the elicited HER-2/neu-specific T-cell immunity. Our findings demonstrate that maximal tumor-specific immune responses may occur toward the end of the vaccination regimen or even after the scheduled vaccines have been completed. Additionally, the presence of tumor antigen-specific immunity prior to vaccination is associated with greater magnitude immune responses.
Salazar
Lupe G
LG
Tumor Vaccine Group, Division of Oncology, University of Washington, Seattle 98109, USA. lsalazar@u.washington.edu
Coveler
Andrew L
AL
Swensen
Ron E
RE
Gooley
Theodore A
TA
Goodell
Vivian
V
Schiffman
Kathy
K
Disis
Mary L
ML
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019496:Cancer Vaccines / Q000276:immunology*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007700:Kinetics; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*; D013995:Time
D019496:Cancer Vaccines; D018719:Erb-b2 Receptor Tyrosine Kinases